A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Individuals
An Interventional, Randomized, Active- Controlled, Phase 1/2/3 Study to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b RNA-Based Vaccine Candidates in COVID-19 Vaccine–Experienced Healthy Individuals
Category & Conditions: Coronavirus Disease (COVID-19)
Medicine: Comirnaty® (BNT162b2)
ClinicalTrials.gov Identifier (NCT): NCT05472038
Protocol ID: C4591044
Open Plain Language Summary Result:
Click here